References
1. Mitra AK, Mawson AR. Neglected Tropical Diseases: Epidemiology and Global Burden. Trop Med Infect Dis. 2017;2(3).
2. Casulli A. New global targets for NTDs in the WHO roadmap 2021-2030. PLoS Negl Trop Dis. 2021;15(5):e0009373.
3. Wilsher E, Jane. The impact of Neglected Tropical Diseases, and their associated stigma, on people’s basic capabilities. Durham, UK2011.
4. Nations U. UN Human Development Report. The Next Frontier: Human Development and the Anthropocene 2020.
5. Sayres L, Hughes BL. Contemporary Understanding of Ebola and Zika Virus in Pregnancy. Clin Perinatol. 2020;47(4):835-846.
6. Collaborators GDD. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1211-1228.
7. Tickell KD, Sharmin R, Deichsel EL, et al. The effect of acute malnutrition on enteric pathogens, moderate-to-severe diarrhoea, and associated mortality in the Global Enteric Multicenter Study cohort: a post-hoc analysis. Lancet Glob Health. 2020;8(2):e215-e224.
8. Hazenberg P, Navaratnam K, Busuulwa P, Waitt C. Anti-Infective Dosing in Special Populations: Pregnancy. Clin Pharmacol Ther. 2021;109(4):977-986.
9. Maharaj AR, Wu H, Zimmerman KO, et al. Pharmacokinetics of Ceftazidime in Children and Adolescents with Obesity. Paediatr Drugs. 2021.
10. Ferro A. Paediatric prescribing: why children are not small adults. Br J Clin Pharmacol. 2015;79(3):351-353.
11. WHO. Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases 2021–20302020.
12. Hotez PJ, Aksoy S, Brindley PJ, Kamhawi S. What constitutes a neglected tropical disease? PLoS Negl Trop Dis. 2020;14(1):e0008001.
13. Reed SL, McKerrow JH. Why Funding for Neglected Tropical Diseases Should Be a Global Priority. Clin Infect Dis. 2018;67(3):323-326.
14. Weld ED, Bailey TC, Waitt C. Ethical issues in therapeutic use and research in pregnant and breastfeeding women. Br J Clin Pharmacol. 2021.
15. Gupta A, Hughes MD, Garcia-Prats AJ, McIntire K, Hesseling AC. Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons. PLoS Med. 2019;16(8):e1002882.
16. Eke AC, Olagunju A, Momper J, et al. Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement. Clin Pharmacol Ther. 2021;110(1):36-48.
17. Colbers A, Mirochnick M, Schalkwijk S, Penazzato M, Townsend C, Burger D. Importance of Prospective Studies in Pregnant and Breastfeeding Women Living With Human Immunodeficiency Virus. Clin Infect Dis. 2019;69(7):1254-1258.
18. Bradley M, Taylor R, Jacobson J, et al. Medicine donation programmes supporting the global drive to end the burden of neglected tropical diseases. Trans R Soc Trop Med Hyg. 2021;115(2):136-144.
19. Gutierrez MM, Pillai G, Felix S, et al. Building Capability for Clinical Pharmacology Research in Sub-Saharan Africa. Clin Pharmacol Ther. 2017;102(5):786-795.
20. Global COVID Vaccination Rates, Our World in Data2021.
21. Booth M. Climate Change and the Neglected Tropical Diseases. Adv Parasitol. 2018;100:39-126.
22. Hotez PJ. The rise of neglected tropical diseases in the ”new Texas”. PLoS Negl Trop Dis. 2018;12(1):e0005581.
23. Gomes MF, de la Fuente-Núñez V, Saxena A, Kuesel AC. Protected to death: systematic exclusion of pregnant women from Ebola virus disease trials. Reprod Health. 2017;14(Suppl 3):172.
24. Mthiyane T, Millard J, Adamson J, et al. -Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and. Antimicrob Agents Chemother. 2020;64(4).
25. Schmith VD, Zhou JJ, Lohmer LRL. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. Clin Pharmacol Ther. 2020;108(4):762-765.
26. Siccardi M, Schapiro J, Di Perri G, Back DJ. The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics. J Antimicrob Chemother. 2020;75(9):2381-2383.
27. Dodds M, Xiong Y, Mouksassi S, et al. Model-informed drug repurposing: A pharmacometric approach to novel pathogen preparedness, response and retrospection. Br J Clin Pharmacol. 2021.
28. Shahriar AA, Alpern JD. Antiparasitic Drugs in the United States-Two Roads to High Prices. Front Sociol. 2020;5:540478.
29. US Food and Drug Administration. Pediatric Research Equity Act of 2003.
30. Qualifying for Pediatric Exclusivity Under Section 505A of the Federal Food, Drug, and Cosmetic Act.
31. Johnson TN, Abduljalil K, Nicolas JM, et al. Use of a physiologically based pharmacokinetic-pharmacodynamic model for initial dose prediction and escalation during a paediatric clinical trial. Br J Clin Pharmacol. 2021;87(3):1378-1389.
32. Stader F, Courlet P, Kinvig H, et al. Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation. Br J Clin Pharmacol. 2021;87(2):458-470.
33. Xu R, Tang H, Chen L, Ge W, Yang J. Developing a physiologically based pharmacokinetic model of apixaban to predict scenarios of drug-drug interactions, renal impairment and paediatric populations. Br J Clin Pharmacol. 2021;87(8):3244-3254.
34. Simpson JA, Jamsen KM, Price RN, et al. Towards optimal design of anti-malarial pharmacokinetic studies. Malar J. 2009;8:189.
35. Standing JF. Understanding and applying pharmacometric modelling and simulation in clinical practice and research. Br J Clin Pharmacol. 2017;83(2):247-254.
36. Holford N. Clinical pharmacology = disease progression + drug action. Br J Clin Pharmacol. 2015;79(1):18-27.
37. Tsamandouras N, Rostami-Hodjegan A, Aarons L. Combining the ’bottom up’ and ’top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. Br J Clin Pharmacol. 2015;79(1):48-55.
38. Drugs for Neglected Tropical Diseases initiatives Strategic Plan 2021-2028. https://dndi.org/wp-content/uploads/2021/03/DNDi-StrategicPlan-2021-2028.pdf.
39. Gogos A, Langmead C, Sullivan JC, Lawrence AJ. The importance of sex differences in pharmacology research. Br J Pharmacol. 2019;176(21):4087-4089.
40. NIH. NIH Policy on Sex as a Biological Variable. https://orwh.od.nih.gov/sex-gender/nih-policy-sex-biological-variable.